Home · Know Your Companions™

Know Your Companions™

A unified map of FDA-defined biomarker requirements by indication. For solid tumors, tumor-agnostic biomarkers appear inline to show where they apply across multiple cancer types.

Approvals
215
Therapies
84
Biomarkers
54
Mapped tests
58
Showing 40 Indications
Acute Myeloid Leukemia (AML)
Oncology • Leukemia
Heme indication3 biomarkers · 6 therapies · 3 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
FLT3 (ITD/TKD)ITD mutations and TKD mutations D835 and I836, ,
IDH1R132 mutations (R132C, R132H, R132G, R132S, and R132L),
IDH2R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W
Aggressive Systemic Mastocytosis
Oncology • Mastocytosis
Heme indication1 biomarker · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
KITD816V
Solid tumor indication8 biomarkers · 6 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRAFV600E
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication9 biomarkers · 6 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
IDH1, IDH2IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Heme indication1 biomarker · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
TP53Deletion chromosome 17p (17p-)
Biliary Tract Cancer
Oncology • Biliary
Solid tumor indication8 biomarkers · 6 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
ERBB2 (HER2)HER-2 protein overexpression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Breast Cancer
Oncology • Breast
Solid tumor indication12 biomarkers · 15 therapies · 14 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRCA1 and BRCA2alterations (including mutations),
ERBB2 (HER2)gene amplification, ,
HER-2 protein overexpression, ,
HER2 ultralow expression (IHC 0 with membrane staining)
HER2-low expression (IHC 1+ or IHC 2+/ISH non-amplified)
ESR1ESR1 missense mutations between codons 310 and 547
PIK3CAAKT1/PTEN alterations
alterations (including mutations)
C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Cervical Cancer
Oncology • Cervix
Solid tumor indication8 biomarkers · 5 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
PD-L1protein expression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Cholangiocarcinoma
Oncology • Bile Duct
Solid tumor indication9 biomarkers · 7 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
FGFR2fusions and select rearrangements
IDH1Single nucleotide variants
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Chronic Myeloid Leukemia (CML)
Oncology • Leukemia
Heme indication1 biomarker · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
t(9;21) Philadelphia chromosomeBCR-ABL fusion
Colorectal Cancer (CRC)
Oncology • Colorectal
Solid tumor indication18 biomarkers · 12 therapies · 14 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A and SULF2Microsatellite instability-High (MSI-H),
BRAFV600E
EGFR (HER1)protein expression,
KRASG12A, G12D, G12R, G12C, G12S, G12V, G13D,
G12C,
KRAS wild-type (absence of mutations in codons 12 and 13),
Mutations in codons 12 and 13 of KRAS gene,
KRAS and NRASwild-type (absence of mutations in exons 2, 3 and 4)
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6, , ,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
1 biomarker · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
AAV Antibodiesserotype rh74
Endometrial Carcinoma (EC)
Oncology • Endometrium
Solid tumor indication9 biomarkers · 7 therapies · 5 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
Not MSI-HighNot Microsatellite Instability-High (Not MSI-H)
proficient mismatch repair (pMMR) proteinsMLH1, PMS2, MSH2 and MSH6
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6, ,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication8 biomarkers · 6 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
FOLR1protein expression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication8 biomarkers · 5 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
PD-L1protein expression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Follicular Lymphoma Tumor
Oncology • Lymphoma
Heme indication1 biomarker · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
EZH2Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene
Gastric and Gastroesophageal Cancer
Oncology • Stomach/GEJ
Solid tumor indication8 biomarkers · 6 therapies · 7 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
ERBB2 (HER2)gene amplification
HER-2 protein overexpression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication9 biomarkers · 6 therapies · 7 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
Claudin 18 (CLDN18)Claudin 18 (CLDN18) protein expression (≥75% viable tumor cells (% TC) staining)
PD-L1protein expression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication8 biomarkers · 6 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
PDGFRAD842V mutation
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication8 biomarkers · 5 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
PD-L1protein expression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Hemophilia A Patients
Hematology • Blood
1 biomarker · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
AAV Antibodiesserotype 5
2 biomarkers · 2 therapies · 2 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
Antithrombin IIIFunctionally active Antithrombin III
ConcizumabTissue factor pathway inhibitor antagonist
Low-Grade Glioma
Oncology • Brain
Solid tumor indication8 biomarkers · 6 therapies · 5 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRAFV600 and BRAF fusions
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Medullary Thyroid Cancer (MTC)
Oncology • Thyroid
Solid tumor indication7 biomarkers · 5 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
RETRET mutations (SNVs, MNVs, and deletions)
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Melanoma
Oncology • Melanoma
Solid tumor indication8 biomarkers · 12 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRAFV600
V600E,
V600E and V600K, , ,
V600E or V600K,
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication11 biomarkers · 9 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRCA1 and BRCA2alterations (including mutations), , ,
BRCA1, BRCA2 and ATMalterations (including mutations)
Homologous recombination repair (HRR) genesBRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication8 biomarkers · 6 therapies · 5 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRAFV600E
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
1 biomarker · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
AAV Antibodiesserotype rh74
Myelodysplastic Syndromes (MDS)
Oncology • Bone Marrow
Heme indication2 biomarkers · 2 therapies · 2 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
IDH1R132 mutations (R132C, R132H, R132G, R132S, and R132L)
PDGFRBPDGFRB gene rearrangement at 5q31~33
Solid tumor indication15 biomarkers · 32 therapies · 20 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
ALKgene rearrangements, , , ,
protein expression, , ,
BRAFV600E,
EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutation, , , , ,
Exon 19 deletions or exon 21 L858R, and T790M
Exon 20 insertions,
L861Q, G719X and S7681
T790M
ERBB2 (HER2)Activating Mutations (SNVs And Exon 20 Insertions)
Activating mutations in the tyrosine kinase domain (SNVs in exons 18-21 and exon 20 insertions)
KRASG12C,
METMET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+)
single nucleotide variants and indels that lead to MET exon 14 skipping,
PD-L1protein expression,
protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%])
protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%])
protein expression (tumor cell staining ≥1%)
protein expression [Tumor Proportion Score (TPS) ≥ 50%]
ROS1fusions,
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions,
TMBTMB ≥ 10 mutations per megabase
1 biomarker · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
Liver iron concentration imagingbased on the proton transverse relaxation rate of MRI images
Obesity
Endocrinology • Metabolic
3 biomarkers · 1 therapy · 1 mapped test
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
POMC, PCSK1 and LEPRVariants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance
Ovarian Cancer
Oncology • Ovary
Solid tumor indication10 biomarkers · 7 therapies · 7 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRCA1 and BRCA2alterations (including mutations),
HRDDeleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Pancreatic Cancer
Oncology • Pancreas
Solid tumor indication9 biomarkers · 6 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRCA1 and BRCA2alterations (including mutations)
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Prostate Cancer
Oncology • Prostate
Solid tumor indication9 biomarkers · 6 therapies · 5 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
BRCA1 and BRCA2alterations (including mutations)
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Synovial sarcoma
Oncology • Soft Tissue
Solid tumor indication9 biomarkers · 6 therapies · 7 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
HLAEligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles. Exclusion alleles: HLA-A*02:05 and its P-group alleles.
Melanoma-associated antigen 4 (MAGE-A4)MAGE-A4 protein overexpression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Thyroid Cancer (TC)
Oncology • Thyroid
Solid tumor indication7 biomarkers · 5 therapies · 6 mapped tests
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Solid tumor indication8 biomarkers · 5 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
PD-L1protein expression
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Urothelial Cancer
Oncology • Bladder
Solid tumor indication9 biomarkers · 7 therapies · 7 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
FGFR3Exon 7: R248C (c.742C>T), S249C (c.746C>G); exon 10: G370C (c.1108G>T) and Y373C (c.1118A>G); and fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3)
PD-L1protein expression (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area)
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase
Uveal Melanoma
Oncology • Eye
Solid tumor indication8 biomarkers · 6 therapies · 6 mapped tests
Indication-specific biomarkers
Select a therapy to open its FDA-approved testing pathway
BiomarkerBiomarker detailsTherapies
HLAHLA-A*02:01
Tumor-agnostic biomarkers that apply to this indication
Solid tumors
BiomarkerBiomarker detailsTherapies
deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6,
MSI-HighMicrosatellite instability-High,
NTRK1, NTRK2 and NTRK3fusions,
RETfusions
TMBTMB ≥ 10 mutations per megabase